Literature DB >> 1649144

Comparison of the immunosuppressive activities of the antimycotic agents itraconazole, fluconazole, ketoconazole and miconazole on human T-cells.

G Pawelec1, G Ehninger, A Rehbein, K Schaudt, K Jaschonek.   

Abstract

Four antifungal agents have been screened in vitro for their immunosuppressive effects on proliferative responses in human mixed lymphocyte cultures (MLC). A hierarchy of inhibitory activity was observed, where itraconazole was greater than ketoconazole greater than miconazole greater than fluconazole, with itraconazole as suppressive as cyclosporin A, and fluconazole completely without suppressive activity. The mechanism of inhibition did not involve blockade of T-cell growth factor production and, consistent with this, interleukin-2-dependent T-cell clone proliferation was blocked by these agents in the same order of decreasing activity as in MLC. The secretion of cytokines without known T-cell growth factor activity (interferon-gamma, tumour necrosis factor-alpha) was also not significantly blocked by these agents. These results therefore demonstrate that antifungal azole drugs may be variably strongly immunosuppressive for human T-lymphocyte proliferation in vitro, but none appear to be so via a mechanism involving inhibition of cytokine secretion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1649144     DOI: 10.1016/0192-0561(91)90111-j

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  8 in total

Review 1.  Severe asthma with fungal sensitization.

Authors:  Ritesh Agarwal
Journal:  Curr Allergy Asthma Rep       Date:  2011-10       Impact factor: 4.806

2.  Failure of itraconazole to prevent T-helper type 2 cell immune deviation: Implications for chronic rhinosinusitis.

Authors:  Joshua L Kennedy; John W Steinke; Lixia Liu; Julie Negri; Larry Borish; Spencer C Payne
Journal:  Am J Rhinol Allergy       Date:  2016-11-01       Impact factor: 2.467

3.  Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection.

Authors:  T Kuhara; K Uchida; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

4.  Impact of different antimycotics on cytokine levels in an in vitro aspergillosis model in human whole blood.

Authors:  Zoe Oesterreicher; Sabine Eberl; Markus Zeitlinger
Journal:  Infection       Date:  2019-08-01       Impact factor: 3.553

5.  Combined effect of fluconazole and thymosin alpha 1 on systemic candidiasis in mice immunosuppressed by morphine treatments.

Authors:  P di Francesco; R Gaziano; I A Casalinuovo; L Belogi; A T Palamara; C Favalli; E Garaci
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

6.  Amphibians acquire resistance to live and dead fungus overcoming fungal immunosuppression.

Authors:  Taegan A McMahon; Brittany F Sears; Matthew D Venesky; Scott M Bessler; Jenise M Brown; Kaitlin Deutsch; Neal T Halstead; Garrett Lentz; Nadia Tenouri; Suzanne Young; David J Civitello; Nicole Ortega; J Scott Fites; Laura K Reinert; Louise A Rollins-Smith; Thomas R Raffel; Jason R Rohr
Journal:  Nature       Date:  2014-07-10       Impact factor: 49.962

Review 7.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

8.  Ketoconazole in atopic dermatitis: therapeutic response is correlated with decrease in serum IgE.

Authors:  O Bäck; A Scheynius; S G Johansson
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.